Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some biotechnology and genome-sciences companies to your portfolio, the PowerShares Dynamic Biotech & Genome ETF (NYS: PBE) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.
ETFs often sport lower expense ratios than their mutual fund cousins. The PowerShares ETF's expense ratio -- its annual fee -- is 0.63%. The fund is fairly small, too, so if you're thinking of buying, beware of possibly large spreads between its bid and ask prices. Consider using a limit order if you want to buy in.
This ETF has performed rather well, beating the world market over the past three and five years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.
The biotechnology and genome arena is a very promising one for investors due to our planet's growing and aging population, which will require more medical care over time. It's not without risks, though, as many new treatments are costly to develop and don't always clear FDA hurdles.
More than a handful of biotech and genome companies had strong performances over the past year. PDL BioPharma (NAS: PDLI) surged 44%, collecting royalties from a slew of medications. It offers a tempting 7.4% dividend yield, but bears worry about a handful of patents that expire in the next few years, and they also note that revenue has already not been growing briskly. Management has said it's seeking other revenue-generating assets.
Cancer-fighter Seattle Genetics (NAS: SGEN) gained 15%, with bulls optimistic about its partnership with Abbott Laboratories (NYS: ABT) (which it recently expanded) and its focus on antibody-drug coagulates, a promising treatment arena without gobs of participants. Its Adcetris, targeting those age 60 or older suffering with newly diagnosed Hodgkin's lymphoma, has recently begun phase 2 trials.
Other companies didn't do as well last year, but could see their fortunes change in the coming years. Isis Pharmaceuticals (NAS: ISIS) only gained 4%, but it had been up much more until recently, when the FDA expressed concerns about its lead drug, Kynamro (aka mipomersen), which is being developed with Sanofi (NYS: SNY) to treat homozygous familial hypercholesterolemia, or HoFH. The FDA is worried about the drug's negative effects on liver functioning, that it creates fat buildup, and that 3% of tested patients are developing abnormal growths.
ImmunoGen (NAS: IMGN) sank by 15% over the past year, and like Seattle Genetics, it doesn't have many competitors to combat. Bulls are pleased with promising results from its late-stage trial of trastuzumab emtansine, or T-DM1, for the treatment of metastatic HER2-positive breast cancer -- though FDA approval should rarely be counted on until it happens.
The big picture
Demand for new medical products isn't going away anytime soon. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.
PDL BioPharma's huge dividend is alluring, but it's not your only road to big income. Check out our special free report outlining nine dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost -- just click here to discover the winners we've picked.
The article A Simple Path to Biotechnology Winners originally appeared on Fool.com.
Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter, owns shares of PDL BioPharma. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend ImmunoGen and PDL BioPharma. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.